John Tilton - 25 Nov 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role: Chief Commercial Officer
Signature: /s/ Jim Engelhart, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 25 Nov 2021
Net transactions value: -$56,851
Form type: 4
Filing time: 26 Nov 2021, 15:33:33 UTC
Next filing: 07 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Options Exercise	$0	+1,250	+47%	$0.000000	3,909	25 Nov 2021	Direct
transaction	BHVN	Common Shares	Tax liability	$56,851	-492	-13%	$115.55^*	3,417	25 Nov 2021	Direct	F1
holding	BHVN	Common Shares						1,614	25 Nov 2021	By JET Ventures LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BHVN	Restricted Share Unit Award	Options Exercise	$0	-1,250	-50%	$0.000000	1,250	25 Nov 2021	Common Shares	1,250		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2	Each restricted share unit represents the contingent right to receive one common share of the issuer.
F3	The reporting person was granted 5,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F4	Not applicable.